查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016585

肌萎缩侧索硬化症 (ALS) 治疗市场规模、份额、趋势和预测：按 ALS 类型、药物类型、诊断方法、治疗方法、分销管道和地区划分，2026-2034 年

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Trends and Forecast by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球肌萎缩侧索硬化症（ALS）治疗市场规模为8.197亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以3.99%的复合年增长率成长，到2034年达到11.777亿美元。目前，北美市场占据主导地位，预计2025年将占56.2%的市场。该地区的市场领先地位得益于其完善的医疗保健基础设施、充足的研究经费以及较高的疾病认知度。此外，该地区还受益于强有力的临床试验监管支持、尖端治疗方法的普及以及完善的医保报销政策，所有这些因素都促成了其在ALS治疗市场的领先地位。

市场成长的主要驱动力是全球肌萎缩侧索硬化症（ALS）发病率的上升，导致对创新治疗方法的需求不断增长。个人化医疗的扩展，以及基因和生物标记研究的进步，使得更具针对性和疗效的疗法成为可能。近期由伦敦玛丽女王大学主导的MIROCALS临床试验就是这类创新的一个例子。该试验透过在标准ALS治疗方案中加入低剂量白细胞介素-2（IL-2LD）取得了令人鼓舞的结果，显示其有可能延缓功能衰退并延长存活期。这项试验凸显了ALS新治疗方法的持续研发。此外，政府为促进罕见疾病治疗研发和孤儿药认定所采取的措施也推动了ALS研究的发展。公共和私营部门投资的增加，以及生物技术公司和製药公司之间的合作，正在加速新治疗方法的发现，从而推动市场扩张。人们对ALS的认识不断提高，并对其毁灭性影响有了更深入的了解，这也促使人们对治疗方法方案的需求不断增长。

在美国，来自国立卫生研究院 (NIH) 等政府机构和私营部门的大量研究经费正推动着肌萎缩侧索硬化症 (ALS) 治疗市场的成长。 ALS 认知宣传活动和支持团体的增加，促使患者活性化参与权益倡导，并提高了对治疗方法的需求。此外，尖端基因和细胞疗法的研发，以及美国食品药物管理局(FDA) 的监管支持，正在促进创新。美国大型生物技术和製药公司的存在，为加速临床试验和提高药物可近性创造了有利环境，进一步推动了市场扩张。

肌萎缩侧索硬化症（ALS）治疗市场趋势：

神经系统疾病发生率增加

神经系统疾病盛行率的不断上升是肌萎缩侧索硬化症 (ALS) 治疗市场的主要趋势之一。根据美国国立卫生研究院 (NIH) 2023 年的报告，全球约有 15% 的人口将受到神经系统疾病的影响，而神经系统疾病是导致身体和认知障碍的主要原因。盛行率的上升正在推动对先进 ALS治疗方法和干预措施的需求。随着人们对神经系统疾病作为一项重大公共卫生问题的认识不断提高，对专业治疗的需求也在增加，宣传活动不断推进，医疗创新也在积极推动，以应对与这些疾病相关的挑战。随着全球医疗保健系统不断调整以应对日益加重的神经退化性疾病负担，预计这一趋势将持续下去。

人口老化加剧了对肌萎缩侧索硬化症（ALS）治疗的需求。

全球人口老化对肌萎缩侧索硬化症（ALS）治疗市场的成长起着至关重要的作用。世界卫生组织（WHO）预测，到2050年，60岁以上人口将达到21亿，80岁以上人口将增加至4.26亿。由于老年人更容易患有ALS等神经退化性疾病，这种人口结构的变化将推动对专业治疗、医疗保健服务和早期诊断的需求成长。随着医疗保健机构日益关注易患ALS及类似疾病的老年人的需求，不断增长的老龄人口是影响ALS治疗市场前景的关键因素。

肌萎缩侧索硬化症治疗领域的突破性创新

肌萎缩侧索硬化症（ALS）治疗的进展正对市场产生重大影响，尤其是在正在进行的临床试验取得成功之后。例如，2025年4月，NeuroSense Therapeutics公司宣布其用于治疗ALS的PARADIGM药物的IIb期临床试验取得了积极成果。该试验表明，用于治疗ALS的在研药物PrimeC在调节微型RNA展现出显着疗效，有望延缓疾病进展，为ALS患者带来新的希望。这些突破性进展凸显了人们对ALS标靶有效治疗方法的关注。随着研究投入的增加和临床试验的持续进展，包括基因治疗和神经保护方面的试验，市场正在见证重大进步，这些进步有望在不久的将来彻底改变ALS的治疗效果。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：肌萎缩侧索硬化症（ALS）治疗的全球市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场细分：依ALS类型划分

  • 散发性肌萎缩性侧索硬化症
  • 遗传性肌萎缩性侧索硬化症

第七章 市场区隔：依药物类型划分

  • 非处方药
  • 新兴药物

第八章 市场区隔：依诊断类型划分

  • 图
  • MRI
  • 血液和尿液检查
  • 腰椎穿刺
  • 肌肉切片检查

第九章 市场区隔：依治疗方式划分

  • 药物
  • 干细胞疗法
  • 其他的

第十章 市场区隔：依分销通路划分

  • 医院药房
  • 零售药房
  • 其他的

第十一章 市场区隔：按地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十二章 SWOT 分析

第十三章：价值链分析

第十四章：波特五力分析

第十五章：价格分析

第十六章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • AB Science
    • Ascend Pharmaceuticals LLC
    • BrainStorm Cell Therapeutics Inc.
    • Corestem Inc.
    • Cytokinetics Inc.
    • Eledon Pharmaceuticals Inc.
    • Ionis Pharmaceuticals Inc.
    • ITF Pharma（Italfarmaco SpA）
    • Mitsubishi Chemical Group Corpotion
    • Revalesio Corporation
    • Treeway BV
Product Code: SR112026A6057

The global amyotrophic lateral sclerosis treatment market size was valued at USD 819.7 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 1,177.7 Million by 2034, exhibiting a CAGR of 3.99% during 2026-2034. North America currently dominates the market, holding a significant market share of 56.2% in 2025. The region leads the market due to robust healthcare infrastructure, extensive research funding, and high disease awareness. The region also benefits from strong regulatory support for clinical trials, access to cutting-edge therapies, and well-established reimbursement policies, contributing to its dominance in the amyotrophic lateral sclerosis treatment market share.

The growth of the market is primarily driven by the increasing demand for innovative therapies due to the rising incidence of ALS worldwide. The expansion of personalized medicine, coupled with advancements in genetic and biomarker research, allows for more targeted and effective treatments. A recent example of such innovation is the MIROCALS clinical trial, led by Queen Mary University of London, which showed promising results by adding low-dose interleukin-2 (IL2LD) to standard ALS treatment, potentially slowing functional decline and extending lifespan. This trial highlights the ongoing development of novel therapies in ALS treatment. Furthermore, government initiatives promoting the development of rare disease treatments and orphan drug designations are encouraging research in ALS. Increased investment from both public and private sectors, alongside collaborations between biotech and pharmaceutical companies, is accelerating the discovery of novel therapies, thus driving market expansion. Enhanced awareness of ALS and its devastating impact also contributes to growing demand for treatment options.

In the United States, the amyotrophic lateral sclerosis treatment market growth is bolstered by strong research funding from both governmental agencies such as the National Institutes of Health (NIH) and private sectors. The rise in ALS awareness campaigns and support groups has led to higher patient advocacy and demand for treatment options. Moreover, the development of cutting-edge gene therapies and cell-based treatments, along with regulatory support from the U.S. Food and Drug Administration (FDA), encourages innovation. The presence of leading biotech and pharmaceutical firms in the U.S. fosters an environment conducive to accelerating clinical trials and improving drug availability, further propelling expansion.

AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET TRENDS:

Rising Incidence of Neurological Disorders

The increasing prevalence of neurological disorders is a key amyotrophic lateral sclerosis treatment market trend. According to a 2023 report by the U.S. National Institutes of Health (NIH), around 15% of individuals globally are affected by neurological conditions, which are the leading cause of physical and cognitive disabilities. This rising incidence is creating a greater need for advanced ALS therapies and interventions. The growing recognition of neurological diseases as a significant public health concern is spurring increased demand for specialized treatments, raising awareness, and fostering medical innovations to address the challenges associated with these disorders. This trend is expected to continue as global healthcare systems adapt to the increasing burden of neurodegenerative diseases.

Expanding Geriatric Population Driving Demand for ALS Treatments

The aging population worldwide is playing a significant role in the growth of the ALS treatment market. By 2050, the World Health Organization (WHO) predicts that the number of people aged 60 and above will reach 2.1 billion, with individuals aged 80 years and over expected to grow to 426 million. As older individuals are more susceptible to neurodegenerative diseases like ALS, this demographic shift will increase the demand for specialized treatments, healthcare services, and early diagnosis initiatives. The expansion of the geriatric population is a key factor influencing the positive amyotrophic lateral sclerosis treatment market outlook, as healthcare providers focus on addressing the needs of an aging population with heightened vulnerability to ALS and similar disorders.

Breakthrough Innovations in ALS Treatment

Advancements in ALS treatment are significantly shaping the market, particularly with the ongoing success of clinical trials. For example, in April 2025, NeuroSense Therapeutics released positive results from its Phase 2b PARADIGM clinical trial for ALS treatment. The trial demonstrated that PrimeC, an experimental ALS treatment, has a notable effect on microRNA modulation, offering new hope for ALS patients by potentially slowing disease progression. Such breakthroughs highlight the growing focus on targeted and effective therapies for ALS. With increasing investment in research and the continued progress of clinical trials, including those focused on gene therapy and neuroprotection, the market is witnessing significant advancements that could revolutionize ALS treatment outcomes in the near future.

AMYOTROPHIC LATERAL SCLEROSIS TREATMENT INDUSTRY SEGMENTATION:

Analysis by ALS Type:

  • Sporadic ALS
  • Familial ALS

Sporadic ALS stand as the largest component in 2025, holding around 68.5% of the market. The sporadic ALS segment dominates the amyotrophic lateral sclerosis (ALS) treatment market due to its higher prevalence compared to familial ALS. This widespread occurrence drives the demand for treatments, research, and healthcare resources dedicated to managing and slowing disease progression. Additionally, the lack of a clear genetic cause in sporadic ALS increases the complexity of treatment, leading to greater focus on developing targeted therapies. Consequently, the large patient population and the need for advanced therapies fuel the market growth in this segment.

Analysis by Drug Type:

  • Marketed Drugs
  • Emerging Drugs

Marketed drugs play a crucial role in the amyotrophic lateral sclerosis (ALS) treatment market by providing immediate solutions to manage the disease's progression. The market is currently driven by FDA-approved therapies such as Rilutek (Riluzole) and Radicava (Edaravone), which help slow ALS progression, extending survival and improving quality of life for patients. As awareness of ALS grows and the demand for effective treatments increases, the marketed drugs segment continues to expand. Enhanced regulatory support, as well as greater insurance coverage, has made these drugs more accessible to a broader patient base. This segment remains pivotal in addressing the unmet needs of ALS patients worldwide, while ongoing research supports the development of next-generation therapies.

Emerging drugs in the ALS treatment market are gaining increasing prominence as researchers focus on innovative therapeutic approaches to address ALS's complex pathology. The emergence of gene therapies, cell-based treatments, and novel oral drugs marks a turning point in ALS management. The development of drugs like PrimeC, currently in clinical trials, demonstrates the potential to modify disease progression through microRNA modulation. Growth drivers for this segment include rising investment in ALS-specific research, advancements in personalized medicine, and the success of early-stage trials. These emerging therapies offer hope for more effective treatments, potentially revolutionizing ALS care by targeting the underlying mechanisms of neurodegeneration.

Analysis by Diagnosis Type:

  • Electromyogram
  • MRI
  • Blood and Urine Tests
  • Spinal Tap
  • Muscle Biopsy

Electromyogram (EMG) plays a crucial role in the diagnosis and management of amyotrophic lateral sclerosis (ALS). It is a primary tool for detecting electrical activity in muscles, allowing healthcare professionals to assess nerve damage, which is a hallmark of ALS. The growing adoption of EMG as a diagnostic tool drives market growth, as early detection is critical for effective disease management. Technological advancements in EMG devices, combined with an increasing number of ALS cases, contribute to its widespread use in clinical settings. Moreover, healthcare awareness and the growing focus on accurate diagnostic procedures further bolster the demand for EMG in ALS treatment.

Magnetic Resonance Imaging (MRI) has become an essential imaging technique for diagnosing and monitoring ALS. While MRI cannot definitively diagnose ALS, it is used to rule out other neurological conditions with similar symptoms, ensuring accurate diagnosis. The use of advanced MRI techniques, such as functional and diffusion tensor imaging, helps in tracking disease progression and monitoring treatment responses. As research into ALS treatments advances, MRI's ability to offer insights into brain and spinal cord abnormalities continues to drive its significance in clinical practice. This growing role in monitoring ALS is spurring the demand for MRI equipment and services within the market.

Blood and urine tests are becoming increasingly important in the diagnosis and monitoring of ALS. These tests help in identifying biomarkers associated with ALS, aiding in early detection and improving disease management. As research into ALS biomarkers advances, blood and urine tests are evolving into essential tools for tracking disease progression and response to treatment. This evolution is driving demand for more advanced diagnostic methods, which is positively impacting the ALS treatment market. The increasing focus on personalized medicine and targeted therapies further emphasizes the importance of blood and urine tests in identifying suitable treatment options for ALS patients.

Analysis by Treatment:

  • Medication
  • Stem Cell Therapy
  • Others

Medication leads the market with around 84.9% of market share in 2025. The medication segment dominates the amyotrophic lateral sclerosis (ALS) treatment market due to the critical role of pharmaceutical therapies in managing the disease. Currently, there are few effective treatment options, making medication essential for slowing disease progression and alleviating symptoms. Drug treatments like riluzole and edaravone are the only FDA-approved options, with ongoing research into new therapies targeting the underlying causes of ALS. As ALS is a progressive neurodegenerative disorder, medications are crucial in extending patients' lifespan and improving quality of life. Furthermore, continued advancements in targeted treatments and clinical trials are further propelling the dominance of the medication segment in the market.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Hospital pharmacies leads the market with around 51.6% of market share in 2025. The hospital pharmacies segment dominates the amyotrophic lateral sclerosis (ALS) treatment market due to their central role in the distribution of specialized medications. Hospitals are primary healthcare settings where ALS patients receive diagnosis, treatment, and continuous care. These pharmacies are equipped with access to advanced drugs, including experimental treatments and those under clinical trials, that are crucial for managing ALS. Furthermore, hospital pharmacies benefit from established relationships with pharmaceutical companies, allowing for faster and more reliable access to ALS therapies. Their ability to provide tailored prescriptions and comprehensive patient management services makes them a key player in the ALS treatment landscape.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 56.2%. North America dominates the amyotrophic lateral sclerosis (ALS) treatment market due to several key factors, including robust healthcare infrastructure, advanced medical research, and high levels of disease awareness. For instance, in July 2025, Klotho Neurosciences' gene therapy candidate, KLTO-202, received orphan drug status from the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). This designation is aimed at supporting the development of treatments for rare diseases. KLTO-202 is designed to deliver instructions for producing a protein that reduces inflammation and oxidative stress, which are critical factors in ALS progression. Preclinical studies have shown that the therapy helps protect nerve cells, improves muscle strength, and slows ALS progression. The company plans to launch a first-in-human trial by the third quarter of 2026, with hopes to further validate its potential as a new ALS treatment. The region benefits from strong support for clinical trials and innovation, with significant investment in ALS research from both public and private sectors. Additionally, comprehensive insurance coverage and well-established reimbursement policies make treatments more accessible to patients. The high incidence of ALS, combined with the growing geriatric population, further increases the demand for specialized care, contributing to North America's dominance in the ALS treatment market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

In 2025, the United States held a market share of around 92% in North America. The United States amyotrophic lateral sclerosis (ALS) treatment market is primarily driven by scientific breakthroughs, regulatory support, and increasing patient advocacy. Advancements in understanding the molecular and genetic underpinnings of ALS, including discoveries related to SOD1 and C9orf72 mutations, are catalyzing the development of targeted therapies such as antisense oligonucleotides, gene therapies, and small-molecule disease modifiers. Regulatory agencies are also streamlining fast-track and orphan drug pathways, which has swiftly translated promising preclinical findings into clinical trials and accelerated approval timelines. For instance, in May 2025, the U.S. Food and Drug Administration (FDA) permitted New York-based BrainStorm Cell Therapeutics Inc. to start the Phase 3b clinical study of its NurOwn (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS). The FDA previously approved the trial design through a Special Protocol Assessment (SPA), ensuring that the study's endpoints and statistical techniques are suitable for the eventual submission of a Biologics License Application (BLA). With this approval, the company can now start enrolling patients for this novel treatment. Additionally, breakthroughs in biomarkers, ranging from imaging modalities to neurofilament proteins, are enabling more precise patient stratification, earlier diagnosis, and improved evaluation of treatment efficacy. Pharmaceutical and biotech investment is also increasing, with numerous collaborations and licensing deals fostering a robust pipeline.

ASIA PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The Asia Pacific amyotrophic lateral sclerosis (ALS) treatment market is expanding due to scientific advancements, growing healthcare infrastructure, and rising patient awareness. Pharmaceutical and biotech firms are expanding clinical trial operations in the region, leveraging increasingly capable research centers in countries such as Japan, South Korea, China, and Australia to gain access to diverse genetic populations and expedite recruitment. Moreover, public and private sector investments to support innovation in neurodegenerative disease therapies are steadily increasing, creating a favorable environment for the development of new ALS treatment therapies. For instance, in May 2025, Ahmedabad-based Zydus Group successfully secured a Fast Track designation from the U.S. Food and Drug Administration (FDA) for its new neuroinflammatory drug, Usnoflast, for the treatment of amyotrophic lateral sclerosis (ALS). This Fast Track designation highlights the growing need for the development of effective treatment therapies for ALS in India. Expanding diagnostic networks and specialist neurology clinics are also facilitating earlier disease recognition and timely intervention, thereby supporting the adoption of ALS treatment therapies.

EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The growth of the Europe amyotrophic lateral sclerosis (ALS) treatment market is largely fueled by medical innovations, regulatory alignment, a large number of geriatric population and patient empowerment. In 2024, the EU population was estimated at 449.3 million people and more than one-fifth (21.6%) of it was aged 65 years and over. Scientific advancements in gene editing and RNA therapeutics, particularly antisense oligonucleotides targeting common ALS-associated mutations, are forming the backbone of a growing clinical pipeline, supported by international funding and research consortia. Harmonized regulatory frameworks across the EU, including adaptive approval schemes and orphan designation incentives, are also expediting market entry for breakthrough therapies. Additionally, patient advocacy groups and European ALS registries are playing a central role in clinical trial recruitment and the collection of real-world data. Health technology assessment bodies are increasingly adopting value-based pricing models that consider long-term disease-modifying effects, improving reimbursement prospects for high-cost treatments. Collaborative partnerships between academic institutions, biotech firms, and pharmaceutical companies are fueling translational research, enabling the production and commercialization of novel treatment therapies.

LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The Latin America amyotrophic lateral sclerosis (ALS) treatment market is experiencing robust growth due to increasing healthcare digitization and increasing awareness among the people in the country. In Brazil, an average of 12,000 patients are diagnosed with ALS each year. As remote care becomes more widely adopted, patients in underserved and rural areas are gaining better access to specialized neurological consultations and ongoing disease management. Public-private collaborations are also supporting investment in rare disease frameworks, creating opportunities for greater funding and awareness. Besides this, efforts to harmonize regulatory standards across countries are streamlining the approval process for innovative treatments, further encouraging market entry.

MIDDLE EAST AND AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET ANALYSIS

The Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) treatment market is experiencing gradual growth, driven by increasing awareness, improving diagnostic capabilities, and a rise in healthcare investments across the region. As reported, in terms of GDP, the aggregate healthcare expenditure in the KSA increased from 4.4% of GDP in 2001 to 5.97% of GDP in 2021. Although ALS remains a relatively rare neurodegenerative disorder, early detection and the availability of treatment options such as riluzole, edaravone, and supportive therapies are expanding. Countries like the UAE and Saudi Arabia are witnessing enhanced access to specialized neurology care, while collaborations with global pharmaceutical companies are supporting the introduction of advanced treatment options.

COMPETITIVE LANDSCAPE:

The competitive landscape of the amyotrophic lateral sclerosis treatment market is dynamic, with numerous players focused on developing innovative therapies to address unmet needs. Companies are heavily investing in research and development to create new drug classes, particularly targeting neuroprotection and disease-modifying treatments. For instance, in November 2024, Eisai Co., Ltd. launched Rozebalamin(R) for Injection 25 mg (mecobalamin) in Japan for the treatment of amyotrophic lateral sclerosis (ALS), marking a significant milestone in ALS treatment. This drug aims to slow the progression of functional impairment in ALS patients. The approval is based on the successful results of the JETALS Phase III clinical trial, which demonstrated the drug's effectiveness compared to a placebo. Strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating progress in clinical trials and bringing new treatments to market faster. The growing focus on personalized medicine and biomarkers for early detection further drives competition. As a result, the amyotrophic lateral sclerosis treatment market forecast predicts continued innovation and a rise in the number of treatment options, increasing market competition and expanding opportunities for growth in the coming years.

The report provides a comprehensive analysis of the competitive landscape in the amyotrophic lateral sclerosis treatment market with detailed profiles of all major companies, including:

  • AB Science
  • Ascend Pharmaceuticals LLC
  • BrainStorm Cell Therapeutics Inc.
  • Corestem Inc.
  • Cytokinetics Inc.
  • Eledon Pharmaceuticals Inc.
  • Ionis Pharmaceuticals Inc.
  • ITF Pharma (Italfarmaco S.p.A)
  • Mitsubishi Chemical Group Corpotion
  • Revalesio Corporation
  • Treeway B.V.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the amyotrophic lateral sclerosis (ALS) treatment market?

2. What is the future outlook of the amyotrophic lateral sclerosis (ALS) treatment market?

3. What are the key factors driving the amyotrophic lateral sclerosis (ALS) treatment market?

4. Which region accounts for the largest amyotrophic lateral sclerosis (ALS) treatment market share?

5. Which are the leading companies in the global amyotrophic lateral sclerosis (ALS) treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Amyotrophic Lateral Sclerosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by ALS Type

  • 6.1 Sporadic ALS
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Familial ALS
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Marketed Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Emerging Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Diagnosis Type

  • 8.1 Electromyogram
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 MRI
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Blood and Urine Tests
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Spinal Tap
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Muscle Biopsy
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Treatment

  • 9.1 Medication
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stem Cell Therapy
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AB Science
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Ascend Pharmaceuticals LLC
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 BrainStorm Cell Therapeutics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Corestem Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Cytokinetics Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Eledon Pharmaceuticals Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
    • 16.3.7 Ionis Pharmaceuticals Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 ITF Pharma (Italfarmaco S.p.A)
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
    • 16.3.9 Mitsubishi Chemical Group Corpotion
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Revalesio Corporation
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Treeway B.V.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Amyotrophic Lateral Sclerosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by ALS Type (in %), 2025
  • Figure 5: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Diagnosis Type (in %), 2025
  • Figure 7: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Treatment (in %), 2025
  • Figure 8: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 9: Global: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Amyotrophic Lateral Sclerosis Treatment (Sporadic ALS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Amyotrophic Lateral Sclerosis Treatment (Sporadic ALS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Amyotrophic Lateral Sclerosis Treatment (Familial ALS) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Amyotrophic Lateral Sclerosis Treatment (Familial ALS) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Amyotrophic Lateral Sclerosis Treatment (Marketed Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Amyotrophic Lateral Sclerosis Treatment (Marketed Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Amyotrophic Lateral Sclerosis Treatment (Emerging Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Amyotrophic Lateral Sclerosis Treatment (Emerging Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Amyotrophic Lateral Sclerosis Treatment (Electromyogram) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Amyotrophic Lateral Sclerosis Treatment (Electromyogram) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Amyotrophic Lateral Sclerosis Treatment (MRI) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Amyotrophic Lateral Sclerosis Treatment (MRI) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Amyotrophic Lateral Sclerosis Treatment (Blood and Urine Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Amyotrophic Lateral Sclerosis Treatment (Blood and Urine Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Amyotrophic Lateral Sclerosis Treatment (Spinal Tap) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Amyotrophic Lateral Sclerosis Treatment (Spinal Tap) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Amyotrophic Lateral Sclerosis Treatment (Muscle Biopsy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Amyotrophic Lateral Sclerosis Treatment (Muscle Biopsy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Amyotrophic Lateral Sclerosis Treatment (Medication) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Amyotrophic Lateral Sclerosis Treatment (Medication) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Amyotrophic Lateral Sclerosis Treatment (Stem Cell Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Amyotrophic Lateral Sclerosis Treatment (Stem Cell Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Amyotrophic Lateral Sclerosis Treatment (Other Treatments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Amyotrophic Lateral Sclerosis Treatment (Other Treatments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Amyotrophic Lateral Sclerosis Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Amyotrophic Lateral Sclerosis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Amyotrophic Lateral Sclerosis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Amyotrophic Lateral Sclerosis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Amyotrophic Lateral Sclerosis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Amyotrophic Lateral Sclerosis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: North America: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: North America: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: United States: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: United States: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Canada: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Canada: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Asia-Pacific: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Asia-Pacific: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: China: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: China: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Japan: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Japan: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: India: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: India: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: South Korea: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: South Korea: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Australia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Australia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Indonesia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Indonesia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Europe: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Europe: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Germany: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Germany: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: France: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: France: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: United Kingdom: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: United Kingdom: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Italy: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Italy: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Spain: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Spain: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Russia: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Russia: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Latin America: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Latin America: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Brazil: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Brazil: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Mexico: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Mexico: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Others: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Others: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market: Breakup by Country (in %), 2025
  • Figure 88: Middle East and Africa: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Global: Amyotrophic Lateral Sclerosis Treatment Industry: SWOT Analysis
  • Figure 90: Global: Amyotrophic Lateral Sclerosis Treatment Industry: Value Chain Analysis
  • Figure 91: Global: Amyotrophic Lateral Sclerosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Amyotrophic Lateral Sclerosis Treatment Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by ALS Type (in Million USD), 2026-2034
  • Table 3: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Diagnosis Type (in Million USD), 2026-2034
  • Table 5: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Treatment (in Million USD), 2026-2034
  • Table 6: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 7: Global: Amyotrophic Lateral Sclerosis Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Amyotrophic Lateral Sclerosis Treatment Market: Competitive Structure
  • Table 9: Global: Amyotrophic Lateral Sclerosis Treatment Market: Key Players